STARTUP PROFILE

Cala Health

COUNTRY
USA
FOUNDED
2014
CATEGORY
Neuromodulation
Pioneering wearable, wrist-based neuromodulation (TAPS) to reduce essential tremor by delivering patient-specific stimulation to the median and radial nerves.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

•
Neurofounders Insights
$   Funding   -
Series C+
MODALITY
Nerve stimulator
FORM FACTOR
Wearable (body)
INTERFACE DEPTH
Non-invasive
INDICATION
Parkinson's
TARGET USER
Patients
REGULATORY STAGE
FDA cleared (510k)
Cala Health occupies a well-defined niche in peripheral neuromodulation with its wrist-worn TAPS therapy, offering patient-specific stimulation for essential tremor without invasive procedures. With FDA clearance and commercial traction, it sits ahead of most wearable neuromodulation startups, though its indication-specific focus limits platform extensibility compared to broader neuromodulation systems.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
#
11
BCI reaches a new scale
30 September – 13 October 2026

Cala launched its next-generation kIQ Plus tremor wearable nationwide for essential tremor and Parkinson's disease. The prescription device adds three selectable stimulation waveforms and recalibration before each session. Company-reported data presented at AAN showed 76-89% of patients achieved at least a one-point improvement in TETRAS performance scores across modes. The device is covered by Medicare for eligible patients.

Articles featuring
Cala Health
No items found.